- Home
- MDRR vs LPCN Comparison
MDRR vs LPCN Comparison
Compare MDRR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- LPCN
- Stock Information
- Founded
- MDRR 2015
- LPCN 1997
- Country
- MDRR United States
- LPCN United States
- Employees
- MDRR N/A
- LPCN N/A
- Industry
- MDRR Real Estate Investment Trusts
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- LPCN Health Care
- Exchange
- MDRR Nasdaq
- LPCN Nasdaq
- Market Cap
- MDRR 15.3M
- LPCN 16.1M
- IPO Year
- MDRR 2018
- LPCN N/A
- Fundamental
- Price
- MDRR $12.05
- LPCN $3.10
- Analyst Decision
- MDRR
- LPCN Strong Buy
- Analyst Count
- MDRR 0
- LPCN 1
- Target Price
- MDRR N/A
- LPCN $10.00
- AVG Volume (30 Days)
- MDRR 2.0K
- LPCN 10.3K
- Earning Date
- MDRR 05-08-2025
- LPCN 05-08-2025
- Dividend Yield
- MDRR 2.16%
- LPCN N/A
- EPS Growth
- MDRR N/A
- LPCN N/A
- EPS
- MDRR 0.02
- LPCN N/A
- Revenue
- MDRR $9,735,127.00
- LPCN $11,198,144.00
- Revenue This Year
- MDRR N/A
- LPCN N/A
- Revenue Next Year
- MDRR N/A
- LPCN N/A
- P/E Ratio
- MDRR $590.86
- LPCN N/A
- Revenue Growth
- MDRR N/A
- LPCN N/A
- 52 Week Low
- MDRR $10.90
- LPCN $2.75
- 52 Week High
- MDRR $15.00
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- MDRR 49.84
- LPCN 46.56
- Support Level
- MDRR $11.00
- LPCN $2.82
- Resistance Level
- MDRR $12.30
- LPCN $3.27
- Average True Range (ATR)
- MDRR 0.50
- LPCN 0.23
- MACD
- MDRR -0.06
- LPCN 0.01
- Stochastic Oscillator
- MDRR 45.18
- LPCN 58.92
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.